Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY – Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 15,265 shares, a decrease of 76.2% from the July 30th total of 64,023 shares. Based on an average trading volume of 128,100 shares, the short-interest ratio is currently 0.1 days.
Sinopharm Group Trading Down 1.8%
Shares of Sinopharm Group stock traded down $0.18 on Thursday, reaching $10.01. The stock had a trading volume of 2,961 shares, compared to its average volume of 88,158. The business’s 50 day moving average is $10.72 and its two-hundred day moving average is $11.87. Sinopharm Group has a 1 year low of $10.00 and a 1 year high of $14.87.
About Sinopharm Group
Sinopharm Group Co, Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co, Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions.
See Also
- Five stocks we like better than Sinopharm Group
- Semtech Stock Rallies on Strong Q2 Results and Raised Guidance
- Marvell’s Big AI Test Comes One Day After NVIDIA’s Blowout Quarter
- NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
- Alphabet Is Building a Base—Could a Breakout Be Next?
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
